ArticleThe Journal of antibiotics2026
Allantopyrone A promotes cross-linking of ubiquitin-specific protease 5 (USP5) and inhibits its deubiquitinase activity by targeting distinct domains.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Allantopyrone A is an α-pyrone metabolite produced by the plant endophytic fungus Allantophomopsis lycopodina KS-97. We previously demonstrated that allantopyrone A decreased the abundance of many components of 26S proteasome fractions while inducing the appearance of an additional protein with a higher apparent molecular mass than known proteasome components. In the present study, we identified this protein as ubiquitin-specific protease 5 (USP5) using mass spectrometry. In cell-based assays, allantopyrone A promoted the cross-linked form of USP5, which was shown by immunoprecipitation to represent a USP5 dimer. The cross-linked form of USP5 was markedly reduced when the C-terminal zinc finger ubiquitin-binding domain (cUBP; residues 175-283) was deleted or when Cys195 was substituted with alanine. Allantopyrone A was also found to reduce the activity of multiple deubiquitinases. USP5 labeling by ubiquitin-vinyl methyl ester was markedly reduced by allantopyrone A or by a Cys335 substitution. Consistent with these biological effects of allantopyrone A on USP5, in silico docking studies suggested that allantopyrone A interacts with Cys195 on the surface of the cUBP domain and is positioned near Cys335 within the catalytic center of the USP domain. These results demonstrate that allantopyrone A promotes USP5 cross-linking and inhibits its deubiquitinase activity through interactions with distinct domains.
Indexed as
Identifiers
42449145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.